Print

Cerulean Pharma Inc. Doses First Patients in Randomized Phase 2 Clinical Study of CRLX101 in Non-Small Cell Lung Cancer  
7/12/2011 9:03:38 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.
//-->